Categories Analysis, Industrials
General Electric is literally going down the drain, sinks up to 10% today
General Electric (GE), the 125-year-old manufacturing veteran, lost as much as $6 billion in market valuation on Friday during intra-day trading, after a key analyst slashed its price target from $10 to $6. The revised price target by JPMorgan analyst Stephen Tusa is at a massive 29% downside from the current trading price.
Tusa’s price target of $6 is the lowest on the stock by any analyst. Taking into account the 17 analysts covering GE, the stock has an average price target of $12.73 with a moderate buy rating. The highest target is $21 given by Justin Bergner of Gabelli. The stock has 7 BUY, 8 HOLD and 2 SELL ratings.
GE stock fell up to 10% during intra-day trading on Friday as it sank to a 9-year low.
Justifying the price target slash, Tusa said in an investor note, “The outcome of GE results was worse than expected on almost all fronts. While liquidity is certainly debatable, we believe this is not really about liquidity, it’s about a deterioration in run rate fundamentals.”
General Electric misses on Q3 estimates, cuts dividend again
General Electric had earlier stated that it expects to miss its own full-year guidance as the manufacturing giant removed John Flannery from its helm. GE board was apparently not happy with Flannery’s pace of restructuring.
Larry Culp, who took charge in October, is currently focusing on rebuilding the ailing power business. He also slashed the quarterly dividend to one penny to free up cash flow, but Tusa was unimpressed by the “restructuring measures.”
“We estimate material dilution from weak fundamentals and portfolio moves, with little in return, going against the notion from a year ago that the company could get $20 [billion] in value without diluting the run rate of earnings/FCF,” Tusa added.
GE stock has lost 55% of its value in the past 52 weeks.
Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
